Don't use PP405 from everychem. it is likely fake. 7/4/2025
PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity PP405 Won't Work Long Term: Hair Follicle Damage Due to Abuse of the ISR System
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
community Reminder: NURTURE those dormant hair follicles for as long as you can until PP405 comes out in 2028-2030
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
community Anyone here have a lot of knowledge on hair follicle stem cells and progenitor cells for PP405?
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
community The mechanism of androgenic alopecia
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
community Can one of you smarty pants explain the PP405 results? Why did they choose to highlight that 31% had 20% increase in density? What about the other 69%? What about other ±% in density? Why is this considered a great result? Thanks.
PP405 shows promise in reactivating dormant hair follicles, with 31% of users experiencing a 20% increase in hair density in a short period. It may work faster than minoxidil and without side effects, but its long-term effectiveness is still uncertain.
Related Research
6 / 6 results
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science
This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
research LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo
PP405 may help hair growth by activating hair follicle stem cells.
research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia
This study found that a majority of dermatologists in Saudi Arabia believe in using vitamins and minerals to treat hair loss but emphasized the need for more research to confirm their effectiveness.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.